COVID-19 in cancer patients on active systemic therapy - Outcomes from LMIC scenario with an emphasis on need for active treatment.
Anant RamaswamyLingaraj NayakNirmalya Roy MoulikManju SengarGirish ChinnaswamyKunal JobanputraMinit J ShahAkhil KapoorAmit JoshiAmit KumarAnant GokarnAvinash BondaBadira Cheriyalinkal ParambilMaya PrasadBhausaheb BagalChetan DhamneGaurav NarulaHasmukh JainJaya GhoshJayashree ThoratJyoti BajpaiNandini Sharrel MenonNavin KhattryPrabhat BhargavaSachin PunatarSeema GuliaShripad BanavaliSudeep GuptaSujay SrinivasSushmita RathTushar VoraVanita NoronhaVijay M PatilVikas OstwalKumar PrabhashPublished in: Cancer medicine (2020)
The mortality rates in cancer patients with COVID-19 who are receiving systemic anti-cancer therapy in LMICSs are marginally higher than that reported in unselected COVID-19 cohorts with prolonged time to viral negativity in a substantial number of patients. The pediatric cancer patients tended to have favorable outcomes.
Keyphrases
- sars cov
- coronavirus disease
- cancer therapy
- end stage renal disease
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- prognostic factors
- cardiovascular events
- cardiovascular disease
- squamous cell carcinoma
- stem cells
- adipose tissue
- metabolic syndrome
- skeletal muscle
- insulin resistance
- cell therapy
- patient reported
- combination therapy